Revista Argentina de Coloproctología COMUNICACIONES Publicación CÁNCER ANAL INVASOR. ANÁLISIS DE LA INCIDENCIA EN GRUPOS DE RIESGO EN UNA SERIE RETROSPECTIVA. RESECCIÓN SIMULTÁNEA LAPAROSCÓPICA DE TUMOR Sociedad COLORRECTAL Y METÁSTASIS HEPÁTICAS. FACTIBILIDAD Argentina de DEL MÉTODO. RESULTADOS PRELIMINARES. Coloproctología Cillo M, Estefanía D,
Medicines issued in hospital in 2009FACTSHEET
NHS Drug Expenditure – Top 10
When the NHS was launched in 1948 it had a budget of £437million (roughly £9billion at
today’s value). In 2008/9 it received over 10 times that amount (more than £100billion).
This equates to an average rise in spending over the full 60-year period of about 4% a year
once inflation has been taken into account. However, in recent years investment levels have
been double that to fund a major modernisation programme.
Some 60% of the NHS budget is used to pay staff. A further 20% pays for drugs and other
supplies, with the remaining 20% split between buildings, equipment and training costs on the
one hand and medical equipment, catering and cleaning on the other. Nearly 80% of the total
budget is distributed by local trusts in line with the particular health priorities in their areas.
The money to pay for the NHS comes directly from taxation. According to independent bodies
such as the King’s Fund, this remains the “cheapest and fairest” way of funding health care
when compared with other systems. The 2008/9 budget roughly equates to a contribution of
£1,980 for every man, woman and child in the UK.
Overall, drug expenditure represents about 10% of NHS drug expenditure. Following the 2010 General Election, the coalition government saw to it that all NICE approved drugs should be made readily available to all NHS England patients, irrespective of where they live, and as a consequence there has been a steady increase in the value of drugs issued in hospitals (secondary care). This equates closely with the fact that the newer drugs positively appraised by NICE tend to be very expensive in terms of acquisition cost (i.e. trade price to the NHS). The overall NHS expenditure on medicines in 2009 was £12.3 billion. The overall NHS expenditure on medicines in 2010 was £12.9 billion. In 2009 hospital use accounted for 30.9% of the total cost, up from 28.8% in 2008. In 2010 hospital use accounted for 31.7 per cent of the total cost, up from 30.9 In 2010, the cost of medicines rose by 5.6% overall but by 13.2% in hospitals In 2009, the cost of medicines rose by 4.8 per cent overall but by 7.7 per cent in In 2010, of the drugs positively appraised by NICE, the greatest overall cost was for atorvastatin but etanercept incurred the greatest cost in hospitals. In 2009, of the drugs positively appraised by NICE, the greatest overall cost was for atorvastatin but adalimumab incurred the greatest cost in hospitals. Table 1. Cost (£000s) of top 10 medicines issued in hospital in 2010 Table 2. Cost (£000s) of top 10 medicines issued in Primary care in 2010 5. Simvastatin (including combinations) mainly generic 82,134.8 6. Ezetimibe (excluding combinations) Ezetrol family 8. Pioglitazone (inc with metformin) Actos family 68,132.9 9. Buprenorphine (inc with naloxone) Subutex family 57,646.7 Table 3. Overall cost (£000s) of top 10 medicines issued in ALL sectors 2010 Table 4. Cost (£000s) of top 10 medicines issued in hospital in 2009 Table 5. Cost (£000s) of top 10 medicines issued in Primary care in 2009 1. Atorvastatin (Lipitor) 321,499.6 5. Simvastatin (including combinations) mainly generic 73,470.9 6. Ezetimibe (excluding combinations) Ezetrol family 8. Simvastatin (excluding combinations) generic 66,753.3 Table 6. Overall cost (£000s) of top 10 medicines issued in ALL sectors 2009 5. Olanzapine (Zyprexa) 123,113.1 6. Trastuzumab (Herceptin) Interestingly, the UK patents for the following brands will/have expire(d) in the following years. Clearly this will have a major impact on future data released in 2012. Due to the complex nature of patent law these dates are best estimates, at the time of writing this article and can not therefore be guaranteed. Sources: The NHS Information Centr If you find this article useful, please visito find more articles that you may be interested in
LEGISPE - Legislação Estadual de Pernambucohttp://legis.alepe.pe.gov.br/legis_inferior_norma.aspx?nl=DE30860 Legislação Inferior Decretos Decreto N° 30.860 DECRETO Nº 30.860, DE 05 DEOUTUBRO DE 2007. Introduz alterações na Consolidação da Legislação Tributária do Estado, relativamente a Convênios ICMS. O GOVERNADOR DO ESTADO , no uso das atribuições